• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

1.650 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.650
Bid (Size) 1.630 (2)
Ask (Size) 1.690 (5)
Prev. Close 1.650
Today's Range 1.650 - 1.650
52wk Range 1.370 - 5.000
Shares Outstanding 5,512,656
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside
October 17, 2025
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
October 15, 2025
From Aprea Therapeutics
Via GlobeNewswire

Performance

YTD
-53.8%
-53.8%
1 Month
+12.2%
+12.2%
3 Month
-4.6%
-4.6%
6 Month
+12.2%
+12.2%
1 Year
-61.6%
-61.6%

More News

Read More
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2025
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 17, 2025
Via Benzinga
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
August 28, 2025
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
August 12, 2025
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 23, 2025
Via Benzinga
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
June 25, 2025
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
May 14, 2025
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
March 31, 2025
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 31, 2025
Via Benzinga
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
March 25, 2025
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
March 11, 2025
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
February 05, 2025
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
December 11, 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 07, 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
October 23, 2024
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 15, 2024
Via Benzinga
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
October 14, 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
October 10, 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
October 09, 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 25, 2024
From Aprea Therapeutics
Via GlobeNewswire
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
September 20, 2024
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
September 16, 2024
From Virtual Investor Conferences
Via GlobeNewswire
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
September 12, 2024
From Virtual Investor Conferences
Via GlobeNewswire

Frequently Asked Questions

Is Aprea Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aprea Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aprea Therapeutics, Inc. - Common Stock trade on?
Aprea Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aprea Therapeutics, Inc. - Common Stock?
The ticker symbol for Aprea Therapeutics, Inc. - Common Stock is APRE on the Nasdaq Stock Market
What is the current price of Aprea Therapeutics, Inc. - Common Stock?
The current price of Aprea Therapeutics, Inc. - Common Stock is 1.650
When was Aprea Therapeutics, Inc. - Common Stock last traded?
The last trade of Aprea Therapeutics, Inc. - Common Stock was at 10/20/25 04:00 PM ET
What is the market capitalization of Aprea Therapeutics, Inc. - Common Stock?
The market capitalization of Aprea Therapeutics, Inc. - Common Stock is 9.10M
How many shares of Aprea Therapeutics, Inc. - Common Stock are outstanding?
Aprea Therapeutics, Inc. - Common Stock has 9M shares outstanding.
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap